Shattuck reports early efficacy for SL-172154 in frontline HR-MDS and TP53m AML

Shattuck Labs, Inc.

HR-MDS: 5/14 evaluable patients achieved CR; 4 achieved mCR with hematologic improvement.
TP53m AML: 2/11 evaluable patients achieved CR; 1 patient with CRi proceeded to allo-HCT.
Grade 3/4 AEs related to SL-172154 reported in 14% of TP53m AML and 18% of HR-MDS patients.
Infusion-related reactions most common TEAE; no destructive anemia observed.
Cohorts expanded; additional data expected mid-2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.